Why does null hypothesis testing with OSDI and AOS matter?

Discovery Biology: Enables robust null hypothesis testing and pathway clarification in DES models.
Screening: Provides reproducible, quantitative outputs for candidate evaluation and assay standardization.
Analytics: Delivers statistical outputs, including linear regression and prevalence rates, for cross-condition comparison.
Translational Research: Supports biomarker alignment and continuity from discovery to preclinical studies.
Enterprise Reuse: Establishes a reusable, objective grading capability for future ophthalmic research.

Null hypothesis testing using both OSDI and AOS outputs enables rigorous validation of disease models and endpoints, reducing mechanistic uncertainty in early discovery. This dual approach supports robust target validation and informs portfolio triage decisions.

How does independent variable isolation in AOS grading fit the pipeline?

AOS software isolates ocular redness as an independent variable, providing objective, quantifiable data for screening and assay development. This isolation enhances reproducibility and supports reliable candidate evaluation in the discovery pipeline.

What do quantitative dependent variable measurements from AOS enable?

Quantitative AOS measurements enable statistical comparison of intervention effects, facilitate linear regression analysis, and support cross-study data integration. These outputs are critical for predictive confidence and translational continuity.

Why are replication requirements in OSDI and AOS assessments important?

Replication of both OSDI and AOS assessments ensures data reliability and cross-functional alignment, supporting collaborative decision-making and reducing risk of false positives in portfolio advancement.

What statistical analysis capabilities are required before implementation?

Implementation requires capabilities for linear regression, prevalence calculation, and significance testing to compare OSDI and AOS outputs. These analyses underpin robust endpoint validation and inform risk-adjusted R&D decisions.